Pfizer and Bristol-Myers Squibb Launch Eliquis Direct-to-Patient Program at 40% Discount

Pfizer and Bristol-Myers Squibb will sell blood thinner Eliquis directly to patients at a discounted price of $346/month, a 40% discount from the US list price. Starting Sept. 8, patients can purchase Eliquis through Eliquis 360 Support. The move follows discussions with the White House and is aimed at making the drug more accessible to patients. However, the program is unlikely to benefit a large number of patients, as over 90% of Eliquis users have insurance coverage.

July 17, 2025 - Bristol-Myers Squibb and Pfizer have announced a new direct-to-patient option for purchasing Eliquis® (apixaban) through their Eliquis 360 Support program. Beginning September 8, 2025, eligible U.S. patients with an Eliquis prescription can purchase the medicine directly through Eliquis 360 Support at a discounted rate of more than 40% less than the current list price [1].

The program, which aims to increase patient access and affordability, will provide direct shipping to patients across all 50 states and Puerto Rico. The discounted price for Eliquis is expected to be around $346 per month, a significant reduction from the current US list price [1].

The move follows discussions with the White House and is part of the companies' ongoing efforts to make critical medicines more accessible to patients. However, the program is unlikely to benefit a large number of patients, as over 90% of Eliquis users have insurance coverage [1].

Eliquis, a prescription medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation, has been prescribed to more than 15 million Americans since its launch. The medicine has resulted in an estimated $3 billion in total healthcare cost savings and avoidance, such as hospitalization and extended rehabilitation needs, for every 100,000 patients treated [1].

The Eliquis 360 Support program provides health education and helps patients understand and navigate their prescription insurance coverage. Eligible patients will be able to purchase Eliquis directly through the program as of September 8, 2025 [1].

References:
[1] https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-and-Pfizer-Announce-Direct-to-Patient-Eliquis-apixaban-Option/default.aspx